Trust Signals
All claims are graded by evidence type. No promotional language. Speculative claims are labeled as such. This page was reviewed by the FormBlends Medical Team and updated 2026-05-29. No financial relationships with Novo Nordisk or Eli Lilly.Key Takeaways
- Phase 2 REDEFINE 1 data showed cagrisema produced roughly 22.7% body weight reduction at 68 weeks, versus up to 22.5% for tirzepatide 15 mg in SURMOUNT-1 at 72 weeks. These are not head-to-head numbers.
- Cagrisema is not FDA approved as of mid-2026. Tirzepatide is approved as Zepbound (obesity) and Mounjaro (type 2 diabetes).
- Tirzepatide uses a single dual-agonist molecule targeting GIP and GLP-1 receptors. Cagrisema is a co-formulation of two separate molecules targeting GLP-1 receptors and amylin receptors.
- Both cause substantial lean mass loss alongside fat loss. Neither has demonstrated a clean fat-only weight loss profile in large human trials.
- Compounded versions of cagrilintide-semaglutide blends available today are not the same as the REDEFINE trial formulation and lack FDA oversight of ratio consistency or purity.
What Is the Bottom Line on Cagrisema vs Tirzepatide?
Cagrisema vs tirzepatide is a comparison between an unapproved late-stage candidate and an approved drug. Phase 2 data suggest cagrisema may match or slightly exceed tirzepatide on weight loss percentage, but cagrisema lacks Phase 3 confirmation, FDA approval, and long-term safety data. Tirzepatide is the evidence-supported choice today.Table of Contents
- How do the mechanisms differ?
- Evidence ledger: what the data actually show
- Which produces more weight loss?
- What are the side effects of each?
- Honest head-to-head table
- What most comparison pages get wrong
- What happens to lean mass?
- How to read a product or protocol: label and COA literacy
- Regulatory and access reality
- FAQ
- Sources
How Do the Mechanisms of Cagrisema and Tirzepatide Differ?
Tirzepatide is a single 39-amino-acid peptide that acts as a co-agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor (GLP-1R). Its GIP activity is roughly equipotent to native GIP at the GIPR, and its GLP-1 activity is approximately 5-fold lower potency than native GLP-1 at GLP-1R, by design, to balance tolerability. This dual incretin action potentiates insulin secretion, reduces glucagon, and suppresses appetite through hypothalamic and brainstem pathways.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Cagrisema is a co-formulation of two distinct molecules in a fixed 1:1 ratio (by dose): cagrilintide, a long-acting amylin analogue, combined with semaglutide, the established GLP-1 receptor agonist. Cagrilintide binds amylin receptors, which are heterodimers of the calcitonin receptor (CALCR) with receptor activity-modifying proteins RAMP1 or RAMP3. These receptors are expressed in the area postrema, nucleus tractus solitarius, and hypothalamic arcuate nucleus. Amylin receptor activation slows gastric emptying, suppresses glucagon, and signals satiety through circuits that do not fully overlap with GLP-1 pathways. The rationale is additive or synergistic satiety signaling from two anatomically and biochemically distinct systems.
The important caveat: receptor-level synergy in preclinical models does not automatically translate to proportionally greater human weight loss. Phase 3 data will test whether the mechanistic hypothesis holds at scale.
Evidence Ledger: What the Data Actually Show
| Claim | Best Evidence Type | Key Trial / Source | Effect Direction | Confidence |
|---|---|---|---|---|
| Cagrisema reduces body weight ~22.7% at 68 weeks | Phase 2 RCT (n=~400) | REDEFINE 1 Phase 2 (Novo Nordisk, reported 2023) | Positive | Moderate (Phase 2 only, not replicated at Phase 3 scale) |
| Tirzepatide reduces body weight up to 22.5% at 72 weeks | Phase 3 RCT (n=2,539) | SURMOUNT-1 (Jastreboff et al., NEJM 2022) | Positive | High |
| Tirzepatide reduces HbA1c ~2.0 to 2.3 percentage points in T2D | Phase 3 RCT program | SURPASS program (Frías et al., NEJM 2021; multiple) | Positive | High |
| Cagrilintide adds weight loss on top of semaglutide vs semaglutide alone | Phase 2 RCT | REDEFINE 1 dose-comparison arms | Positive | Moderate |
| GIP receptor agonism in tirzepatide contributes independently to weight loss | Mechanism plus Phase 3 data | Preclinical and translational data; tirzepatide characterization literature | Positive | Moderate |
| Weight regain after stopping tirzepatide is ~two-thirds of loss within one year | Phase 3 withdrawal RCT (n=670) | SURMOUNT-4 (Aronne et al., JAMA 2024) | Negative (regain) | High |
| Cagrisema improves lean mass ratio vs fat mass ratio vs semaglutide alone | Phase 2 subgroup analysis | REDEFINE 1 body composition sub-analysis (Novo Nordisk, 2023) | Tentatively positive | Low (small n, not independently replicated) |
| Cardiovascular outcomes benefit with tirzepatide in obesity | Phase 3 CV outcomes trial | SURMOUNT-MMO (ongoing as of 2026) | Pending | Very Low (data not available) |
Which Produces More Weight Loss?
The honest answer is: we do not know yet, because no head-to-head trial exists. What we have are trials conducted at different times, with different populations, different follow-up durations, and different titration schedules.
SURMOUNT-1 enrolled adults with a BMI of 30 or above, or 27 with at least one comorbidity, and excluded people with type 2 diabetes. The 15 mg tirzepatide arm achieved a mean weight reduction of 22.5% at 72 weeks (Jastreboff et al., NEJM 2022). REDEFINE 1 Phase 2 data for cagrisema showed approximately 22.7% weight reduction at 68 weeks in adults with overweight or obesity without diabetes (Novo Nordisk data disclosed at conferences and in regulatory documents, 2023). The numerical similarity is striking but not statistically comparable across trials.
Phase 3 REDEFINE trials are ongoing. Until those read out and are published in peer-reviewed form, any statement that cagrisema definitively outperforms tirzepatide is speculative. The Phase 2 signal is genuinely encouraging and warrants the Phase 3 investment, but Phase 2 often overestimates effect size.
What Are the Side Effects of Each?
Both drugs share the same dominant side-effect profile: nausea, vomiting, diarrhea, and constipation, largely driven by slowed gastric motility through GLP-1 and amylin pathway activity. In SURMOUNT-1, GI adverse events led to discontinuation in roughly 4.3% of the tirzepatide 15 mg group versus 0.9% on placebo.
Cagrisema's distinct safety signal in REDEFINE 1 included higher rates of injection site reactions compared to semaglutide alone, likely attributable to the cagrilintide component. Calcitonin receptor-mediated effects, including potential effects on bone turnover, are a biological concern with long-term amylin-pathway stimulation, though no clinical bone signal was reported in Phase 2.
Tirzepatide has a well-mapped safety profile across tens of thousands of patient-years in the SURPASS and SURMOUNT programs. Cagrisema has not yet reached that scale of exposure. That asymmetry matters when advising someone choosing between them.
Both carry a class warning for thyroid C-cell tumors (based on rodent data) as GLP-1 receptor agonists. Cagrisema carries this for its semaglutide component.
Honest Head-to-Head Comparison Table
| Attribute | Cagrisema | Tirzepatide | Winner / Caveat |
|---|---|---|---|
| FDA approval status | Not approved (Phase 3) | Approved (Zepbound, Mounjaro) | Tirzepatide wins clearly |
| Peak weight loss (best available data) | ~22.7% (Phase 2) | ~22.5% (Phase 3, 15 mg) | Effectively tied; cagrisema Phase 2 data not confirmed at Phase 3 |
| Receptor targets | GLP-1R + amylin receptors (CALCR/RAMP1, CALCR/RAMP3) | GLP-1R + GIPR | Different pathways, no clear winner on mechanism alone |
| Glycemic (T2D) evidence | Limited Phase 2 data | Extensive Phase 3 SURPASS program | Tirzepatide wins for T2D indication |
| Side-effect characterization | Phase 2 only; injection site reactions notable | Well-characterized across large Phase 3 trials | Tirzepatide has more safety data; not necessarily safer |
| Dosing convenience | Once weekly (co-formulation) | Once weekly | Tie |
| Current access | Clinical trial or unregulated compounding only | Prescription, commercially available | Tirzepatide wins for patients today |
| Long-term safety follow-up | None published beyond Phase 2 | Multiple multi-year datasets | Tirzepatide wins |
| Lean mass preservation (relative) | Tentatively better in Phase 2 sub-analysis | ~10-17% of weight loss from lean mass (SURMOUNT-1 data) | Cagrisema tentatively better; very low confidence |
| CV outcomes data | None | SURMOUNT-MMO ongoing; SURPASS-CVOT showed CV benefit in T2D | Tirzepatide wins (for T2D); obesity CV data pending for both |
What Most Comparison Pages Get Wrong
The compounding pharmacy problem. A large number of people searching "cagrisema" are actually looking to obtain it now, outside a trial. Several compounding pharmacies offer cagrilintide-semaglutide blends. These are not cagrisema. The REDEFINE trial uses a Novo Nordisk co-formulation with precisely characterized peptide ratios, excipients, pH buffering, and release kinetics. A compounded blend of cagrilintide (itself sourced from peptide contract manufacturers with variable purity certifications) mixed with compounded semaglutide introduces at least three variables the trial does not have: uncertain cagrilintide purity, uncertain ratio accuracy at the reconstituted dose, and unknown stability of the combination under real-world storage conditions. You cannot extrapolate the 22.7% weight loss figure to a compounded product. This is not a hypothetical concern. FDA inspections of compounding facilities have found potency deviations and sterility failures in GLP-1 peptide products. Anyone claiming to offer "cagrisema" outside a registered clinical trial is offering something categorically different from what the trial studied.
Phase 2 optimism bias. Most pages present Phase 2 efficacy data as if it were equivalent to Phase 3 data. It is not. Phase 2 trials are powered for signal detection, not definitive efficacy. Effect sizes frequently shrink in Phase 3 as populations broaden and placebo responses become more variable. Cagrisema's 22.7% figure should be read as a promising signal, not a proven outcome.
Ignoring the semaglutide baseline. Cagrisema contains semaglutide 2.4 mg, the same dose used in STEP 1 for obesity. STEP 1 showed roughly 14.9% weight loss with semaglutide alone (Wilding et al., NEJM 2021). The incremental weight loss attributable to cagrilintide on top of semaglutide is therefore in the range of roughly 7 to 8 percentage points in Phase 2. That additive contribution is real and biologically interesting, but framing cagrisema's total number against tirzepatide without noting the semaglutide base is misleading.
What Happens to Lean Mass with Each?
Weight loss drugs reduce total mass, and some of that reduction is always lean mass. In SURMOUNT-1, dual-energy X-ray absorptiometry sub-studies showed that lean mass accounted for roughly 10 to 17% of total weight lost with tirzepatide at various doses, depending on dose and follow-up window (data presented at ADA 2023, Jastreboff et al.).
Cagrisema Phase 2 body composition sub-analyses suggested a lean-to-fat loss ratio that compared favorably to semaglutide alone, with a proportionally larger fraction of fat mass lost. Whether this holds in Phase 3 at the full sample size is unknown. The amylin pathway has some theoretical basis for preferential fat mobilization in animal models, but this has not been rigorously confirmed in humans.
For both drugs, the clinical implication is the same: resistance training is important during treatment to minimize lean mass loss. This is not drug-specific advice; it applies to all significant caloric-deficit interventions.
How to Read a Protocol or Product: Label and COA Literacy
If you are evaluating a compounded peptide product claiming to be cagrisema or to replicate the REDEFINE formulation, here is what to look for:
| What to Check | What It Should Show | Red Flag |
|---|---|---|
| Certificate of Analysis (COA) | HPLC purity above 98% for research-grade peptides; endotoxin limits should meet applicable USP or compendial standards for the intended route of administration; moisture content stated | No COA, COA from unaccredited lab, or purity below 95% |
| Peptide sequence identification | Mass spectrometry confirmation of molecular weight matching published cagrilintide sequence | Identity confirmed by appearance only or generic "amylin analogue" labeling |
| Ratio specification | Defined mg doses of each component per vial, not just "combined" mg | No ratio stated; "equivalent to clinical dose" without specifics |
| Storage conditions | Refrigerated (2 to 8 degrees Celsius) before reconstitution; use within stated window after reconstitution | Room-temperature shipping without cold pack; no reconstituted stability data |
| Sterility testing | USP 71 sterility or equivalent | No sterility test, or visual inspection only |
Even with all boxes checked, a compounded product is not the REDEFINE trial drug. The formulation details of cagrisema (buffer composition, pH, co-formulation excipients, preservatives) are proprietary to Novo Nordisk and not publicly available for replication.
Regulatory and Access Reality
Tirzepatide received FDA approval as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023. It is commercially available via prescription in the United States, though supply constraints and cost (list price roughly $1,000 per month before insurance) remain barriers. Compounded semaglutide and tirzepatide were permitted during FDA drug shortage periods, though this regulatory landscape continues to evolve.
Cagrisema (Novo Nordisk's internal designation CagriSema or INN co-formulation) is in Phase 3 REDEFINE trials as of 2026. It does not have an NDA submitted or approved. A realistic FDA approval timeline, assuming positive Phase 3 readouts, would not precede 2027 at the earliest. Patients who want access to cagrisema today have no legitimate commercial route. Clinical trial enrollment through ClinicalTrials.gov is the only evidence-grade option.
Frequently Asked Questions
What is cagrisema and how does it differ from tirzepatide?
Cagrisema is a fixed-ratio co-formulation of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist). Tirzepatide is a single molecule that acts as a dual GIP and GLP-1 receptor agonist. They target weight loss through different receptor combinations.
Which produces more weight loss, cagrisema or tirzepatide?
Phase 2 REDEFINE 1 data for cagrisema showed approximately 22.7% body weight reduction at 68 weeks. Tirzepatide's SURMOUNT-1 Phase 3 trial showed up to 22.5% at 72 weeks at the 15 mg dose. Cagrisema appears comparable or marginally higher, but direct head-to-head trials do not yet exist and Phase 3 data for cagrisema are pending.
Is cagrisema FDA approved?
No. As of mid-2026, cagrisema remains in Phase 3 clinical development (REDEFINE program by Novo Nordisk). Tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) is FDA approved.
What are the main side effects of cagrisema vs tirzepatide?
Both cause predominantly GI side effects: nausea, vomiting, and diarrhea. Cagrisema's amylin component adds calcitonin-receptor-mediated effects; injection site reactions were more common in REDEFINE 1 than with semaglutide alone. Tirzepatide's GI profile is well-characterized across large Phase 3 trials.
How does the amylin mechanism in cagrisema add to semaglutide?
Cagrilintide acts on amylin receptors (CALCR/RAMP1 and CALCR/RAMP3 complexes) in the area postrema and hypothalamus, slowing gastric emptying and reducing food intake through pathways distinct from GLP-1. The combination produces greater satiety signaling than semaglutide alone in preclinical and early clinical data.
Does tirzepatide help with blood sugar better than cagrisema?
Tirzepatide has robust Phase 3 glycemic data across the SURPASS program for type 2 diabetes, showing HbA1c reductions of roughly 2.0 to 2.3 percentage points at the highest doses. Cagrisema's glycemic data are more limited; it is not currently developed as a primary diabetes therapy.
Can you use cagrisema right now outside a clinical trial?
Not through approved channels. Cagrisema is not FDA approved or commercially available. Some compounding pharmacies have offered cagrilintide-semaglutide combinations, but these are not equivalent to the precisely characterized REDEFINE trial formulation and carry unknown purity and ratio consistency.
What does the evidence say about lean mass preservation with these agents?
Both agents cause significant lean mass loss as part of total weight reduction. SURMOUNT-1 sub-analyses showed roughly 10 to 17% of total weight loss as lean mass with tirzepatide. Cagrisema Phase 2 data suggest a similar or slightly improved lean-to-fat loss ratio, but this is not yet confirmed in Phase 3.
How do the dosing schedules compare?
Both are once-weekly subcutaneous injections. Tirzepatide escalates from 2.5 mg to a maximum of 15 mg over roughly 20 weeks. Cagrisema in REDEFINE trials used a co-formulation with semaglutide 2.4 mg paired with cagrilintide at escalating doses up to 2.4 mg, also once weekly.
Which is better for someone who already tried semaglutide?
Tirzepatide adds GIP receptor agonism on top of GLP-1, offering a different incretin mechanism. Cagrisema adds amylin-pathway signaling on top of semaglutide. Both have shown additional weight loss in patients with prior GLP-1 exposure in small datasets, but no large trial has randomized prior-semaglutide patients to either agent head-to-head.
What happens to weight after stopping either drug?
Weight regain after stopping is substantial for both. SURMOUNT-4 showed roughly two-thirds of tirzepatide weight loss was regained within one year of stopping. No equivalent long-term discontinuation data exist for cagrisema yet, but the biology of weight regain after pharmacologic suppression of appetite applies to both.
Sources
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515.
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
- Novo Nordisk. CagriSema Phase 2 REDEFINE 1 results. Presented at European Association for the Study of Diabetes (EASD) annual meeting, 2023.
- Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg (CagriSema). Lancet. 2021;397(10286):1736-1748.
- US Food and Drug Administration. FDA approves new medication for chronic weight management (tirzepatide). November 8, 2023. FDA.gov.
- Kalra S, Bhattacharya S. Amylin analogues in the management of obesity and diabetes. Journal of Pakistan Medical Association. Review reference for amylin receptor biology.
Disclaimers
Platform: FormBlends provides educational science content. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before starting, stopping, or modifying any treatment.
Research Compound / Regulatory Status: Cagrisema is an investigational compound. It is not FDA approved for any indication as of the date of this publication. Information about compounded products is provided for educational awareness only and does not constitute endorsement.
Results: Clinical trial weight loss percentages represent population means under controlled conditions. Individual results vary and cannot be predicted. The weight loss figures cited are from specific trials and should not be treated as guaranteed outcomes for any patient or product.
Trademark: Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends has no affiliation with either company.